{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T11:57:37Z","timestamp":1785585457048,"version":"3.56.0"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"DOI":"10.1007\/s11906-026-01380-9","type":"journal-article","created":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T11:32:23Z","timestamp":1785583943000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MASLD and Cardiovascular Risk: Mechanisms and Implications for Clinical Practice"],"prefix":"10.1007","volume":"28","author":[{"given":"Sainan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Toutoungy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janvi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indira","family":"Bhavsar-Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6264-2573","authenticated-orcid":false,"given":"Lisa B.","family":"VanWagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,1]]},"reference":[{"issue":"6","key":"1380_CR1","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/hep.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966\u201386. https:\/\/doi.org\/10.1097\/hep.0000000000000520.","journal-title":"Hepatology"},{"issue":"7","key":"1380_CR2","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMra2412865","volume":"393","author":"G Targher","year":"2025","unstructured":"Targher G, Valenti L, Byrne CD. Metabolic Dysfunction-Associated Steatotic Liver Disease. N Engl J Med. 2025;393(7):683\u201398. https:\/\/doi.org\/10.1056\/NEJMra2412865.","journal-title":"N Engl J Med"},{"issue":"20","key":"1380_CR3","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148(20):1606\u201335. https:\/\/doi.org\/10.1161\/CIR.0000000000001184.","journal-title":"Circulation"},{"issue":"4","key":"1380_CR4","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73(4):691\u2013702. https:\/\/doi.org\/10.1136\/gutjnl-2023-330595.","journal-title":"Gut"},{"issue":"2","key":"1380_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jama.2025.19615","volume":"335","author":"H Tilg","year":"2026","unstructured":"Tilg H, Petta S, Stefan N, Targher G. Metabolic Dysfunction\u2013Associated Steatotic Liver Disease in Adults: A Review. JAMA. 2026;335(2):163\u201374. https:\/\/doi.org\/10.1001\/jama.2025.19615.","journal-title":"JAMA"},{"issue":"1","key":"1380_CR6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/s2468-1253(24)00310-8","volume":"10","author":"JJ Gries","year":"2025","unstructured":"Gries JJ, Lazarus JV, Brennan PN, Siddiqui MS, Targher G, Lang CC, et al. Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease. Lancet Gastroenterol Hepatol. 2025;10(1):82\u201394. https:\/\/doi.org\/10.1016\/s2468-1253(24)00310-8.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"20","key":"1380_CR7","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/j.jacc.2025.08.100","volume":"86","author":"MS Khan","year":"2025","unstructured":"Khan MS, Javaid SS, Dinani A, Wegermann K, Pandey A, Bhatt AS, et al. The Basics of Metabolic Dysfunction-Associated Steatotic Liver Disease for Cardiologists: Pathophysiology, Diagnosis, and Treatment. J Am Coll Cardiol. 2025;86(20):1861\u201384. https:\/\/doi.org\/10.1016\/j.jacc.2025.08.100.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"1380_CR8","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2337\/dci24-0094","volume":"48","author":"K Cusi","year":"2025","unstructured":"Cusi K, Abdelmalek MF, Apovian CM, Balapattabi K, Bannuru RR, Barb D, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 2025;48(7):1057\u201382. https:\/\/doi.org\/10.2337\/dci24-0094.","journal-title":"Diabetes Care"},{"key":"1380_CR9","doi-asserted-by":"publisher","unstructured":"Yanai H, Adachi H, Hakoshima M, Iida S, Katsuyama H. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments. Int J Mol Sci. 2023;24(20). https:\/\/doi.org\/10.3390\/ijms242015473.","DOI":"10.3390\/ijms242015473"},{"key":"1380_CR10","doi-asserted-by":"publisher","unstructured":"Mustafa A, Kite C, Lagojda L, Dallaway A, Chatha KK, Than NN, et al. Cardiovascular Disease in the Context of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Comprehensive Narrative Review. Int J Mol Sci. 2025;26(23). https:\/\/doi.org\/10.3390\/ijms262311275.","DOI":"10.3390\/ijms262311275"},{"issue":"7","key":"1380_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s11892-024-01542-6","volume":"24","author":"Y Castillo-N\u00fa\u00f1ez","year":"2024","unstructured":"Castillo-N\u00fa\u00f1ez Y, Almeda-Valdes P, Gonz\u00e1lez-G\u00e1lvez G, Arechavaleta-Granell MDR. Metabolic dysfunction-associated steatotic liver disease and atherosclerosis. Curr Diab Rep. 2024;24(7):158\u201366. https:\/\/doi.org\/10.1007\/s11892-024-01542-6.","journal-title":"Curr Diab Rep"},{"issue":"1","key":"1380_CR12","doi-asserted-by":"publisher","first-page":"24953","DOI":"10.1038\/s41598-025-10380-9","volume":"15","author":"J Jeong","year":"2025","unstructured":"Jeong J, Han S, Park G-M, Park S, Jeon Y-J, Lim S, et al. Association of metabolic dysfunction-associated steatotic liver disease and steatosis-associated fibrosis estimator with subclinical coronary atherosclerosis: observation cohort study. Sci Rep. 2025;15(1):24953. https:\/\/doi.org\/10.1038\/s41598-025-10380-9.","journal-title":"Sci Rep"},{"key":"1380_CR13","doi-asserted-by":"publisher","unstructured":"Ionescu VA, Gheorghe G, Bacalbasa N, Diaconu CC. Metabolic Dysfunction-Associated Steatotic Liver Disease: Pathogenetic Links to Cardiovascular Risk. Biomolecules. 2025;15(2). https:\/\/doi.org\/10.3390\/biom15020163.","DOI":"10.3390\/biom15020163"},{"key":"1380_CR14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.freeradbiomed.2020.02.025","volume":"152","author":"Z Chen","year":"2020","unstructured":"Chen Z, Tian R, She Z, Cai J, Li H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med. 2020;152:116\u201341. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2020.02.025.","journal-title":"Free Radic Biol Med"},{"key":"1380_CR15","doi-asserted-by":"publisher","first-page":"1690443","DOI":"10.3389\/fimmu.2025.1690443","volume":"16","author":"X Qian","year":"2025","unstructured":"Qian X, Sun J, Li F, Xu L, Hu X, Dong N, et al. Inflammasomes as the molecular hub of cardiovascular-metabolic-immune comorbidity networks. Front Immunol. 2025;16:1690443. https:\/\/doi.org\/10.3389\/fimmu.2025.1690443.","journal-title":"Front Immunol"},{"key":"1380_CR16","doi-asserted-by":"publisher","first-page":"109395","DOI":"10.1016\/j.thromres.2025.109395","volume":"253","author":"DE Gonz\u00e1lez-Mendoza","year":"2025","unstructured":"Gonz\u00e1lez-Mendoza DE, Fern\u00e1ndez-Nogueira F, Uribe M, Ch\u00e1vez-Tapia NC, Nu\u00f1o-L\u00e1mbarri N. Hemostatic alterations in metabolic dysfunction-associated steatotic liver disease (MASLD) and their link to venous thromboembolism (VTE). Thromb Res. 2025;253:109395. https:\/\/doi.org\/10.1016\/j.thromres.2025.109395.","journal-title":"Thromb Res"},{"issue":"2","key":"1380_CR17","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jacc.2021.11.007","volume":"79","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Byrne CD, Benfari G, Bonapace S, Simon TG, Targher G. Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2022;79(2):180\u201391. https:\/\/doi.org\/10.1016\/j.jacc.2021.11.007.","journal-title":"J Am Coll Cardiol"},{"key":"1380_CR18","doi-asserted-by":"publisher","unstructured":"Chen VL, Kuppa A, Oliveri A, Chen Y, Ponnandy P, Patel PB, et al. Human genetics of metabolic dysfunction-associated steatotic liver disease: from variants to cause to precision treatment. J Clin Invest. 2025;135(7). https:\/\/doi.org\/10.1172\/jci186424.","DOI":"10.1172\/jci186424"},{"issue":"2","key":"1380_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/s2213-8587(24)00318-8","volume":"13","author":"N Stefan","year":"2025","unstructured":"Stefan N, Yki-J\u00e4rvinen H, Neuschwander-Tetri BA. Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. Lancet Diabetes Endocrinol. 2025;13(2):134\u201348. https:\/\/doi.org\/10.1016\/s2213-8587(24)00318-8.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"16","key":"1380_CR20","doi-asserted-by":"publisher","first-page":"e70932","DOI":"10.1096\/fj.202403293RR","volume":"39","author":"Z Xin","year":"2025","unstructured":"Xin Z, Wang Z, Chu M. Insights Into Intestinal Flora in Metabolic Dysfunction-Associated Steatotic Liver Disease. Faseb j. 2025;39(16):e70932. https:\/\/doi.org\/10.1096\/fj.202403293RR.","journal-title":"Faseb j"},{"key":"1380_CR21","doi-asserted-by":"publisher","unstructured":"Islam K, Kongsomboonchoke P, Chayanupatkul M, Tumkosit M, Chattranukulchai P, Prombutara P, et al. Gut Dysbiosis and Plasma Trimethylamine Oxide Are Associated with Subclinical Coronary Atherosclerosis in Obese Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease. Nutrients. 2025;17(17). https:\/\/doi.org\/10.3390\/nu17172759.","DOI":"10.3390\/nu17172759"},{"issue":"6","key":"1380_CR22","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1210\/endrev\/bnaf018","volume":"46","author":"J Dong","year":"2025","unstructured":"Dong J, Dennis K, Venkatakrishnan R, Hodson L, Tomlinson JW. The Impact of Estrogen Deficiency on Liver Metabolism: Implications for Hormone Replacement Therapy. Endocr Rev. 2025;46(6):790\u2013809. https:\/\/doi.org\/10.1210\/endrev\/bnaf018.","journal-title":"Endocr Rev"},{"issue":"5","key":"1380_CR23","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/hep.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797\u2013835. https:\/\/doi.org\/10.1097\/hep.0000000000000323.","journal-title":"Hepatology"},{"key":"1380_CR24","doi-asserted-by":"publisher","unstructured":"Weiskirchen R, Lonardo A. Sex Hormones and Metabolic Dysfunction-Associated Steatotic Liver Disease. Int J Mol Sci. 2025;26(19). https:\/\/doi.org\/10.3390\/ijms26199594.","DOI":"10.3390\/ijms26199594"},{"issue":"5","key":"1380_CR25","doi-asserted-by":"publisher","first-page":"e4691","DOI":"10.1016\/j.ajog.2025.04.007","volume":"233","author":"MY Miao","year":"2025","unstructured":"Miao MY, Han WW, Lyu JQ, Liu ZY, Jiang W, Zhang Z, et al. Female reproductive factors and metabolic dysfunction-associated steatotic liver disease: an integrated analysis of population cohort, liver imaging, and genetic data. Am J Obstet Gynecol. 2025;233(5):e4691\u201354. https:\/\/doi.org\/10.1016\/j.ajog.2025.04.007.","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"1380_CR26","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/hep4.1841","volume":"6","author":"J Vieira Barbosa","year":"2022","unstructured":"Vieira Barbosa J, Milligan S, Frick A, Broestl J, Younossi Z, Afdhal NH, et al. Fibrosis-4 Index as an Independent Predictor of Mortality and Liver-Related Outcomes in NAFLD. Hepatol Commun. 2022;6(4):765\u201379. https:\/\/doi.org\/10.1002\/hep4.1841.","journal-title":"Hepatol Commun"},{"issue":"2","key":"1380_CR27","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jhep.2022.10.034","volume":"78","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal AJ, Foucquier J, Younossi ZM, Harrison SA, Newsome PN, Chan WK, et al. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores. J Hepatol. 2023;78(2):247\u201359. https:\/\/doi.org\/10.1016\/j.jhep.2022.10.034.","journal-title":"J Hepatol"},{"issue":"2","key":"1380_CR28","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1053\/j.gastro.2024.03.017","volume":"167","author":"LA van Kleef","year":"2024","unstructured":"van Kleef LA, Francque SM, Prieto-Ortiz JE, Sonneveld MJ, Sanchez-Luque CB, Prieto-Ortiz RG, et al. Metabolic Dysfunction-Associated Fibrosis 5 (MAF-5) Score Predicts Liver Fibrosis Risk and Outcome in the General Population With Metabolic Dysfunction. Gastroenterology. 2024;167(2):357\u2013e679. https:\/\/doi.org\/10.1053\/j.gastro.2024.03.017.","journal-title":"Gastroenterology"},{"issue":"3","key":"1380_CR29","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1002\/hep.30163","volume":"69","author":"SJ Daniels","year":"2019","unstructured":"Daniels SJ, Leeming DJ, Eslam M, Hashem AM, Nielsen MJ, Krag A, et al. ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis. Hepatology. 2019;69(3):1075\u201386. https:\/\/doi.org\/10.1002\/hep.30163.","journal-title":"Hepatology"},{"issue":"1","key":"1380_CR30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12933-024-02572-w","volume":"24","author":"Y Qiao","year":"2025","unstructured":"Qiao Y, Wang Y, Chen C, Huang Y, Zhao C. Association between triglyceride-glucose (TyG) related indices and cardiovascular diseases and mortality among individuals with metabolic dysfunction-associated steatotic liver disease: a cohort study of UK Biobank. Cardiovasc Diabetol. 2025;24(1):12. https:\/\/doi.org\/10.1186\/s12933-024-02572-w.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1380_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12933-025-03034-7","volume":"25","author":"L Pan","year":"2025","unstructured":"Pan L, Shen M, Liu Y, Huang C, Lin R, Qin G, et al. Proteomic signature of metabolic dysfunction-associated steatotic liver disease and risk of atherosclerotic cardiovascular disease. Cardiovasc Diabetol. 2025;25(1):20. https:\/\/doi.org\/10.1186\/s12933-025-03034-7.","journal-title":"Cardiovasc Diabetol"},{"key":"1380_CR32","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2026.01.047","author":"F Kanwal","year":"2026","unstructured":"Kanwal F, Bril F, Wai-Sun Wong V, Adams LA, Pfotenhauer K, Skolnik N, et al. Clinical Care Pathway for the Risk Stratification and Management of Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. Gastroenterology. 2026. https:\/\/doi.org\/10.1053\/j.gastro.2026.01.047.","journal-title":"Gastroenterology"},{"issue":"20","key":"1380_CR33","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1001\/jama.2021.19569","volume":"326","author":"A Aminian","year":"2021","unstructured":"Aminian A, Al-Kurd A, Wilson R, Bena J, Fayazzadeh H, Singh T, et al. Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. JAMA. 2021;326(20):2031\u201342. https:\/\/doi.org\/10.1001\/jama.2021.19569.","journal-title":"JAMA"},{"key":"1380_CR34","doi-asserted-by":"publisher","unstructured":"Diabetes* ADAPPCf. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes\u20142026. Diabetes Care. 2025;49(Supplement_1):S61-S88. https:\/\/doi.org\/10.2337\/dc26-S004","DOI":"10.2337\/dc26-S004"},{"issue":"10","key":"1380_CR35","doi-asserted-by":"publisher","first-page":"109147","DOI":"10.1016\/j.jdiacomp.2025.109147","volume":"39","author":"E Muzurovi\u0107","year":"2025","unstructured":"Muzurovi\u0107 E, Topi\u0107 G, Todorovi\u0107 N, Rizzo M, Ze\u010devi\u0107 K. The prevalence and correlates of advanced fibrosis in patients with and without diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: A cross-sectional study. J Diabetes Complications. 2025;39(10):109147. https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109147.","journal-title":"J Diabetes Complications"},{"issue":"6","key":"1380_CR36","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","volume":"42","author":"PB Duell","year":"2022","unstructured":"Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, Arteriosclerosis, et al. Thromb Vascular Biology. 2022;42(6):e168\u201385. https:\/\/doi.org\/10.1161\/ATV.0000000000000153.","journal-title":"Thromb Vascular Biology"},{"issue":"3","key":"1380_CR37","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"EASL-EASD-EASO","year":"2024","unstructured":"EASL-EASD-EASO. Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031.","journal-title":"J Hepatol"},{"key":"1380_CR38","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003918","author":"D Jayabalan","year":"2026","unstructured":"Jayabalan D, Dhakal S, Chandra J, Fasser DA, Jeffrey GP, Garas G, et al. The Impact of Body Weight Change on Liver Histology in Metabolic Dysfunction-Associated Steatotic Liver Disease Across Various Histological Endpoints: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2026. https:\/\/doi.org\/10.14309\/ajg.0000000000003918.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"1380_CR39","doi-asserted-by":"publisher","first-page":"113753","DOI":"10.4254\/wjh.v18.i1.113753","volume":"18","author":"AW Schwartz","year":"2026","unstructured":"Schwartz AW, Park EY, Ilagan-Ying YC, Zimmerman ZE, Bollinger B, Ying LD, et al. Impact of multidisciplinary steatotic liver disease management on bariatric surgery referral and clinical outcomes: A retrospective cohort study. World J Hepatol. 2026;18(1):113753. https:\/\/doi.org\/10.4254\/wjh.v18.i1.113753.","journal-title":"World J Hepatol"},{"issue":"1","key":"1380_CR40","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1186\/s12916-025-04320-7","volume":"23","author":"VA Arita","year":"2025","unstructured":"Arita VA, Cabezas MC, Hern\u00e1ndez Vargas JA, Trujillo-C\u00e1ceres SJ, Mendez Pernicone N, Bridge LA, et al. Effects of Mediterranean diet, exercise, and their combination on body composition and liver outcomes in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials. BMC Med. 2025;23(1):502. https:\/\/doi.org\/10.1186\/s12916-025-04320-7.","journal-title":"BMC Med"},{"issue":"5","key":"1380_CR41","doi-asserted-by":"publisher","first-page":"950","DOI":"10.14309\/ajg.0000000000003379","volume":"120","author":"AK Singal","year":"2025","unstructured":"Singal AK, Wong RJ, Dasarathy S, Abdelmalek MF, Neuschwander-Tetri BA, Limketkai BN, et al. ACG Clinical Guideline: Malnutrition and Nutritional Recommendations in Liver Disease. Am J Gastroenterol. 2025;120(5):950\u201372. https:\/\/doi.org\/10.14309\/ajg.0000000000003379.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"1380_CR42","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1053\/j.gastro.2020.11.051","volume":"160","author":"ZM Younossi","year":"2021","unstructured":"Younossi ZM, Corey KE, Lim JK. AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology. 2021;160(3):912\u20138. https:\/\/doi.org\/10.1053\/j.gastro.2020.11.051.","journal-title":"Gastroenterology"},{"issue":"19","key":"1380_CR43","doi-asserted-by":"publisher","first-page":"e70134","DOI":"10.1002\/mnfr.70134","volume":"69","author":"PC Agu","year":"2025","unstructured":"Agu PC, Lu J, Hidden Hunger. A Forgotten Comorbidity of Metabolic-Syndrome-Associated Fatty Liver Disease. Mol Nutr Food Res. 2025;69(19):e70134. https:\/\/doi.org\/10.1002\/mnfr.70134.","journal-title":"Mol Nutr Food Res"},{"issue":"1","key":"1380_CR44","doi-asserted-by":"publisher","first-page":"8675","DOI":"10.1038\/s41598-025-92858-0","volume":"15","author":"T Ryu","year":"2025","unstructured":"Ryu T, Chae SY, Lee J, Han JW, Yang H, Chung BS, et al. Multivitamin supplementation and its impact in metabolic dysfunction-associated steatotic liver disease. Sci Rep. 2025;15(1):8675. https:\/\/doi.org\/10.1038\/s41598-025-92858-0.","journal-title":"Sci Rep"},{"issue":"18","key":"1380_CR45","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","volume":"362","author":"AJ Sanyal","year":"2010","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. N Engl J Med. 2010;362(18):1675\u201385. https:\/\/doi.org\/10.1056\/NEJMoa0907929.","journal-title":"N Engl J Med"},{"issue":"16","key":"1380_CR46","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1001\/jama.2011.520","volume":"305","author":"JE Lavine","year":"2011","unstructured":"Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305(16):1659\u201368. https:\/\/doi.org\/10.1001\/jama.2011.520.","journal-title":"JAMA"},{"issue":"23","key":"1380_CR47","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1001\/jama.2022.8970","volume":"327","author":"UPST Force","year":"2022","unstructured":"Force UPST. Vitamin, Mineral, and Multivitamin Supplementation to Prevent Cardiovascular Disease and Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;327(23):2326\u201333. https:\/\/doi.org\/10.1001\/jama.2022.8970.","journal-title":"JAMA"},{"issue":"1","key":"1380_CR48","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/apt.70169","volume":"62","author":"Y Peng","year":"2025","unstructured":"Peng Y, Liu F, Wang P, Gong J, Zhou H, Gu J, et al. Association Between Volume, Intensity and Rhythm of Physical Activity Measured by Accelerometer and Risk of All-Cause and Cause-Specific Mortality in Individuals With MASLD. Aliment Pharmacol Ther. 2025;62(1):48\u201358. https:\/\/doi.org\/10.1111\/apt.70169.","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"1380_CR49","doi-asserted-by":"publisher","first-page":"e70226","DOI":"10.1111\/liv.70226","volume":"45","author":"S Zelber-Sagi","year":"2025","unstructured":"Zelber-Sagi S, Paik JM, Ivancovsky-Wajcmen D, Henry L, Yilmaz Y, Alqahtani SA, et al. Weekend Warrior Exercise Pattern Protects Against MASLD and Mortality Comparable to Regular Exercise: National Cohort Study. Liver Int. 2025;45(8):e70226. https:\/\/doi.org\/10.1111\/liv.70226.","journal-title":"Liver Int"},{"key":"1380_CR50","doi-asserted-by":"publisher","unstructured":"Han E, Woo SY, Jeon JY, Kang ES, Cha B-S, Lee B-W, et al. Impact of physical activities in metabolic dysfunction associated steatotic liver disease, sarcopenia, and cardiovascular disease. Diabetes Res Clin Pract. 2025;224. https:\/\/doi.org\/10.1016\/j.diabres.2025.112209.","DOI":"10.1016\/j.diabres.2025.112209"},{"issue":"9","key":"1380_CR51","doi-asserted-by":"publisher","first-page":"e227","DOI":"10.1161\/atvbaha.124.321214","volume":"44","author":"H Wu","year":"2024","unstructured":"Wu H, Wei J, Chen W, Chen L, Zhang J, Wang N, et al. Leisure Sedentary Behavior, Physical Activities, and Cardiovascular Disease Among Individuals With Metabolic Dysfunction-Associated Fatty Liver Disease. Arterioscler Thromb Vasc Biol. 2024;44(9):e227\u201337. https:\/\/doi.org\/10.1161\/atvbaha.124.321214.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"1380_CR52","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1001\/jamainternmed.2025.1809","volume":"185","author":"P Ochoa-Allemant","year":"2025","unstructured":"Ochoa-Allemant P, Hubbard RA, Kaplan DE, Serper M. Adverse Liver Outcomes, Cardiovascular Events, and Mortality in Steatotic Liver Disease. JAMA Intern Med. 2025;185(8):986\u201395. https:\/\/doi.org\/10.1001\/jamainternmed.2025.1809.","journal-title":"JAMA Intern Med"},{"issue":"5","key":"1380_CR53","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1053\/j.gastro.2017.08.012","volume":"153","author":"LB VanWagner","year":"2017","unstructured":"VanWagner LB, Ning H, Allen NB, Ajmera V, Lewis CE, Carr JJ, et al. Alcohol Use and Cardiovascular Disease Risk in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2017;153(5):1260\u2013e723. https:\/\/doi.org\/10.1053\/j.gastro.2017.08.012.","journal-title":"Gastroenterology"},{"issue":"4","key":"1380_CR54","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1056\/NEJMra1816604","volume":"383","author":"FB Dam RMv, Hu","year":"2020","unstructured":"Dam RMv, Hu FB, Willett WC. Coffee, Caffeine, and Health. N Engl J Med. 2020;383(4):369\u201378. https:\/\/doi.org\/10.1056\/NEJMra1816604.","journal-title":"N Engl J Med"},{"key":"1380_CR55","doi-asserted-by":"publisher","unstructured":"Yoo JJ, Park MY, Cho EJ, Yu SJ, Kim SG, Kim YJ, et al. Smoking Increases the Risk of Hepatocellular Carcinoma and Cardiovascular Disease in Patients with Metabolic-Associated Fatty Liver Disease. J Clin Med. 2023;12(9). https:\/\/doi.org\/10.3390\/jcm12093336.","DOI":"10.3390\/jcm12093336"},{"key":"1380_CR56","doi-asserted-by":"publisher","first-page":"175628482513313","DOI":"10.1177\/17562848251331315","volume":"18","author":"K Yang","year":"2025","unstructured":"Yang K, Lee J, Han JW, Yang H, Chae SY, Chung BS, et al. A comprehensive analysis of the impact of smoking on adverse clinical outcomes of steatotic liver diseases. Th Adv Gastroenterol. 2025;18:17562848251331315. https:\/\/doi.org\/10.1177\/17562848251331315.","journal-title":"Th Adv Gastroenterol"},{"issue":"1","key":"1380_CR57","doi-asserted-by":"publisher","first-page":"24627","DOI":"10.1038\/s41598-025-09985-x","volume":"15","author":"X Jia","year":"2025","unstructured":"Jia X, Zou C, Lu N, Lu Q, Xie C. Obstructive sleep apnea is ralated to metabolic dysfunction associated steatotic liver disease in type 2 diabetes mellitus. Sci Rep. 2025;15(1):24627. https:\/\/doi.org\/10.1038\/s41598-025-09985-x.","journal-title":"Sci Rep"},{"key":"1380_CR58","doi-asserted-by":"publisher","unstructured":"Channapragada TV, Brenner CR, Guruswamy K, Katamreddy R, Pandian AT, Pendala V, et al. Does Continuous Positive Airway Pressure Improve Liver Outcomes in MASLD with Obstructive Sleep Apnea? A Systematic Review. J Clin Med. 2025;15(1). https:\/\/doi.org\/10.3390\/jcm15010225.","DOI":"10.3390\/jcm15010225"},{"issue":"1","key":"1380_CR59","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/ajcn\/nqz042","volume":"110","author":"SR Sharpton","year":"2019","unstructured":"Sharpton SR, Maraj B, Harding-Theobald E, Vittinghoff E, Terrault NA. Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Am J Clin Nutr. 2019;110(1):139\u201349. https:\/\/doi.org\/10.1093\/ajcn\/nqz042.","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"1380_CR60","doi-asserted-by":"publisher","first-page":"2541035","DOI":"10.1080\/19490976.2025.2541035","volume":"17","author":"B Groenewegen","year":"2025","unstructured":"Groenewegen B, Ruissen MM, Crossette E, Menon R, Prince AL, Norman JM, et al. Consecutive fecal microbiota transplantation for metabolic dysfunction-associated steatotic liver disease: a randomized controlled trial. Gut Microbes. 2025;17(1):2541035. https:\/\/doi.org\/10.1080\/19490976.2025.2541035.","journal-title":"Gut Microbes"},{"issue":"2","key":"1380_CR61","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/hep.0000000000001333","volume":"83","author":"WH Ng","year":"2026","unstructured":"Ng WH, Yeo YH, Kim H, Seki E, Rees J, Ma KS, et al. Renin-angiotensin-aldosterone system inhibitor use improves clinical outcomes in patients with metabolic dysfunction-associated steatotic liver diseases: Target trial emulation using real-world data. Hepatology. 2026;83(2):333\u201343. https:\/\/doi.org\/10.1097\/hep.0000000000001333.","journal-title":"Hepatology"},{"issue":"2","key":"1380_CR62","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/hep.32294","volume":"76","author":"X Zhang","year":"2022","unstructured":"Zhang X, Wong GL, Yip TC, Tse YK, Liang LY, Hui VW, et al. Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease. Hepatology. 2022;76(2):469\u201382. https:\/\/doi.org\/10.1002\/hep.32294.","journal-title":"Hepatology"},{"issue":"2","key":"1380_CR63","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jhep.2025.08.017","volume":"84","author":"XD Zhou","year":"2026","unstructured":"Zhou XD, Lian LY, Chen QF, Kim SU, Cheuk-Fung Yip T, Petta S, et al. Effect of hypertension on long-term adverse clinical outcomes and liver fibrosis progression in MASLD. J Hepatol. 2026;84(2):254\u201365. https:\/\/doi.org\/10.1016\/j.jhep.2025.08.017.","journal-title":"J Hepatol"},{"issue":"21","key":"1380_CR64","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, \u00d8stergaard LH, Long MT, Kj\u00e6r MS, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025;392(21):2089\u201399. https:\/\/doi.org\/10.1056\/NEJMoa2413258.","journal-title":"N Engl J Med"},{"issue":"11","key":"1380_CR65","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Gaal LFV, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183.","journal-title":"N Engl J Med"},{"issue":"24","key":"1380_CR66","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563.","journal-title":"N Engl J Med"},{"issue":"2","key":"1380_CR67","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403347.","journal-title":"N Engl J Med"},{"issue":"23","key":"1380_CR68","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1161\/CIRCULATIONAHA.125.074545","volume":"151","author":"N Marx","year":"2025","unstructured":"Marx N, Deanfield JE, Mann JFE, Arechavaleta R, Bain SC, Bajaj HS, et al. Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial. Circulation. 2025;151(23):1639\u201350. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.125.074545.","journal-title":"Circulation"},{"issue":"11","key":"1380_CR69","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1056\/NEJMoa2500969","volume":"393","author":"S Wharton","year":"2025","unstructured":"Wharton S, Lingvay I, Bogdanski P, Vale RDd, Jacob S, Karlsson T, et al. Oral Semaglutide at a Dose of 25\u00a0mg in Adults with Overweight or Obesity. N Engl J Med. 2025;393(11):1077\u201387. https:\/\/doi.org\/10.1056\/NEJMoa2500969.","journal-title":"N Engl J Med"},{"key":"1380_CR70","doi-asserted-by":"publisher","unstructured":"Kitsunai H, Shinozaki Y, Furusawa S, Kitao N, Ito M, Kurihara H, et al. The Effects of Oral Semaglutide on Hepatic Fibrosis in Subjects with Type 2 Diabetes in Real-World Clinical Practice: A Post Hoc Analysis of the Sapporo-Oral SEMA Study. Pharmaceuticals (Basel). 2025;18(1). https:\/\/doi.org\/10.3390\/ph18010129.","DOI":"10.3390\/ph18010129"},{"issue":"4","key":"1380_CR71","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. Tirzepatide for Metabolic Dysfunction\u2013Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024;391(4):299\u2013310. https:\/\/doi.org\/10.1056\/NEJMoa2401943.","journal-title":"N Engl J Med"},{"issue":"3","key":"1380_CR72","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2206038.","journal-title":"N Engl J Med"},{"issue":"3","key":"1380_CR73","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/dom.15410","volume":"26","author":"P Karakasis","year":"2024","unstructured":"Karakasis P, Patoulias D, Fragakis N, Klisic A, Rizzo M. Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: A systematic review and multilevel meta-analysis. Diabetes Obes Metab. 2024;26(3):1090\u2013104. https:\/\/doi.org\/10.1111\/dom.15410.","journal-title":"Diabetes Obes Metab"},{"issue":"24","key":"1380_CR74","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","volume":"393","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls SJ, Pavo I, Bhatt DL, Buse JB, Prato SD, Kahn SE, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025;393(24):2409\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2505928.","journal-title":"N Engl J Med"},{"issue":"15","key":"1380_CR75","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"issue":"4","key":"1380_CR76","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1812389.","journal-title":"N Engl J Med"},{"key":"1380_CR77","doi-asserted-by":"publisher","first-page":"e083735","DOI":"10.1136\/bmj-2024-083735","volume":"389","author":"J Lin","year":"2025","unstructured":"Lin J, Huang Y, Xu B, Gu X, Huang J, Sun J, et al. Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial. BMJ. 2025;389:e083735. https:\/\/doi.org\/10.1136\/bmj-2024-083735.","journal-title":"BMJ"},{"issue":"10","key":"1380_CR78","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1007\/s00125-018-4702-3","volume":"61","author":"N Sattar","year":"2018","unstructured":"Sattar N, Fitchett D, Hantel S, George JT, Zinman B. Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME\u00ae trial. Diabetologia. 2018;61(10):2155\u201363. https:\/\/doi.org\/10.1007\/s00125-018-4702-3.","journal-title":"Diabetologia"},{"issue":"11","key":"1380_CR79","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1210\/clinem\/dgad249","volume":"108","author":"AN Borisov","year":"2023","unstructured":"Borisov AN, Kutz A, Christ ER, Heim MH, Ebrahimi F. Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients With Diabetes Mellitus: New Insights From CANVAS. J Clin Endocrinol Metab. 2023;108(11):2940\u20139. https:\/\/doi.org\/10.1210\/clinem\/dgad249.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1380_CR80","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.2337\/dc21-2049","volume":"45","author":"Y Takeshita","year":"2022","unstructured":"Takeshita Y, Honda M, Harada K, Kita Y, Takata N, Tsujiguchi H, et al. Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial. Diabetes Care. 2022;45(9):2064\u201375. https:\/\/doi.org\/10.2337\/dc21-2049.","journal-title":"Diabetes Care"},{"issue":"9","key":"1380_CR81","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1111\/jdi.14246","volume":"15","author":"D Ito","year":"2024","unstructured":"Ito D, Shimizu S, Haisa A, Yanagisawa S, Inoue K, Saito D, et al. Long-term effects of ipragliflozin and pioglitazone on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow-up of a randomized, 24 week, active-controlled trial: Effect of ipragliflozin in MASLD. J Diabetes Investig. 2024;15(9):1220\u201330. https:\/\/doi.org\/10.1111\/jdi.14246.","journal-title":"J Diabetes Investig"},{"issue":"19","key":"1380_CR82","doi-asserted-by":"publisher","first-page":"e779","DOI":"10.1161\/CIR.0000000000000766","volume":"141","author":"SV Arnold","year":"2020","unstructured":"Arnold SV, Bhatt DL, Barsness GW, Beatty AL, Deedwania PC, Inzucchi SE, et al. Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. Circulation. 2020;141(19):e779\u2013806. https:\/\/doi.org\/10.1161\/CIR.0000000000000766.","journal-title":"Circulation"},{"issue":"Supplement1","key":"1380_CR83","doi-asserted-by":"publisher","first-page":"S216","DOI":"10.2337\/dc26-S010","volume":"49","author":"10","year":"2026","unstructured":"10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Supplement1):S216\u201345. https:\/\/doi.org\/10.2337\/dc26-S010.","journal-title":"Diabetes Care"},{"issue":"9756","key":"1380_CR84","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/s0140-6736(10)61272-x","volume":"376","author":"VG Athyros","year":"2010","unstructured":"Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010;376(9756):1916\u201322. https:\/\/doi.org\/10.1016\/s0140-6736(10)61272-x.","journal-title":"Lancet"},{"issue":"10","key":"1380_CR85","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1097\/MCG.0b013e31819c392e","volume":"43","author":"A Nelson","year":"2009","unstructured":"Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial. J Clin Gastroenterol. 2009;43(10):990\u20134. https:\/\/doi.org\/10.1097\/MCG.0b013e31819c392e.","journal-title":"J Clin Gastroenterol"},{"issue":"6","key":"1380_CR86","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1097\/hep.0000000000000278","volume":"78","author":"SR Sharpton","year":"2023","unstructured":"Sharpton SR, Loomba R. Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC. Hepatology. 2023;78(6):1896\u2013906. https:\/\/doi.org\/10.1097\/hep.0000000000000278.","journal-title":"Hepatology"},{"issue":"18","key":"1380_CR87","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"N Engl J Med"},{"issue":"22","key":"1380_CR88","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"N Engl J Med"},{"issue":"31","key":"1380_CR89","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.2174\/1381612824666181010123127","volume":"24","author":"E Theocharidou","year":"2018","unstructured":"Theocharidou E, Papademetriou M, Reklou A, Sachinidis A, Boutari C, Giouleme O. The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors. Curr Pharm Des. 2018;24(31):3654\u20137. https:\/\/doi.org\/10.2174\/1381612824666181010123127.","journal-title":"Curr Pharm Des"},{"issue":"12","key":"1380_CR90","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.4254\/wjh.v12.i12.1258","volume":"12","author":"M Shafiq","year":"2020","unstructured":"Shafiq M, Walmann T, Nutalapati V, Gibson C, Zafar Y. Effects of proprotein convertase subtilisin\/kexin type-9 inhibitors on fatty liver. World J Hepatol. 2020;12(12):1258\u201366. https:\/\/doi.org\/10.4254\/wjh.v12.i12.1258.","journal-title":"World J Hepatol"},{"issue":"23","key":"1380_CR91","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","volume":"73","author":"DM Charytan","year":"2019","unstructured":"Charytan DM, Sabatine MS, Pedersen TR, Im K, Park JG, Pineda AL, et al. Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. J Am Coll Cardiol. 2019;73(23):2961\u201370. https:\/\/doi.org\/10.1016\/j.jacc.2019.03.513.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1380_CR92","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00424-025-03069-5","volume":"477","author":"S Hummelgaard","year":"2025","unstructured":"Hummelgaard S, Kresse JC, Jensen MS, Glerup S, Weyer K. Emerging roles of PCSK9 in kidney disease: lipid metabolism, megalin regulation and proteinuria. Pflugers Arch. 2025;477(6):773\u201386. https:\/\/doi.org\/10.1007\/s00424-025-03069-5.","journal-title":"Pflugers Arch"},{"issue":"Supplement1","key":"1380_CR93","doi-asserted-by":"publisher","first-page":"S246","DOI":"10.2337\/dc26-S011","volume":"49","author":"11","year":"2026","unstructured":"11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Supplement1):S246\u201360. https:\/\/doi.org\/10.2337\/dc26-S011.","journal-title":"Diabetes Care"},{"issue":"3","key":"1380_CR94","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1001\/jama.2025.20834","volume":"335","author":"BL Neuen","year":"2026","unstructured":"Neuen BL, Fletcher RA, Anker SD, Bhatt DL, Butler J, Cherney DZI, et al. SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis. JAMA. 2026;335(3):233\u201344. https:\/\/doi.org\/10.1001\/jama.2025.20834.","journal-title":"JAMA"},{"issue":"5","key":"1380_CR95","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1053\/j.ajkd.2024.11.013","volume":"85","author":"JY Chen","year":"2025","unstructured":"Chen JY, Hsu TW, Liu JH, Pan HC, Lai CF, Yang SY, et al. Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials. Am J Kidney Dis. 2025;85(5):555\u2013e691. https:\/\/doi.org\/10.1053\/j.ajkd.2024.11.013.","journal-title":"Am J Kidney Dis"},{"issue":"24","key":"1380_CR96","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021;385(24):2252\u201363. https:\/\/doi.org\/10.1056\/NEJMoa2110956.","journal-title":"N Engl J Med"},{"key":"1380_CR97","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000001608","author":"MB Bansal","year":"2025","unstructured":"Bansal MB, Patton H, Morgan TR, Carr RM, Dranoff JA, Allen AM. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance. Hepatology. 2025. https:\/\/doi.org\/10.1097\/hep.0000000000001608.","journal-title":"Hepatology"},{"issue":"1","key":"1380_CR98","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/hep.0000000000001112","volume":"81","author":"VL Chen","year":"2025","unstructured":"Chen VL, Morgan TR, Rotman Y, Patton HM, Cusi K, Kanwal F, et al. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance. Hepatology. 2025;81(1):312\u201320. https:\/\/doi.org\/10.1097\/hep.0000000000001112.","journal-title":"Hepatology"},{"issue":"6","key":"1380_CR99","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000.","journal-title":"N Engl J Med"},{"issue":"11","key":"1380_CR100","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","volume":"29","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Taub R, Neff GW, Lucas KJ, Labriola D, Moussa SE, et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2023;29(11):2919\u201328. https:\/\/doi.org\/10.1038\/s41591-023-02603-1.","journal-title":"Nat Med"},{"issue":"3","key":"1380_CR101","first-page":"313","volume":"110","author":"S Ohri","year":"2024","unstructured":"Ohri S, Summa M. Resmetirom (Rezdiffra) for the Treatment of Noncirrhotic Nonalcoholic Steatohepatitis With Moderate to Advanced Fibrosis. Am Fam Physician. 2024;110(3):313\u20134.","journal-title":"Am Fam Physician"},{"key":"1380_CR102","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000001453","author":"CE Ndumele","year":"2026","unstructured":"Ndumele CE, Rodriguez F, Dixon DL, Khan SS, Mukherjee D, Bajaj M, et al. 2026 AHA\/ACC\/ADA\/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026. https:\/\/doi.org\/10.1161\/cir.0000000000001453.","journal-title":"Circulation"},{"issue":"4","key":"1380_CR103","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","volume":"391","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024;391(4):311\u20139. https:\/\/doi.org\/10.1056\/NEJMoa2401755.","journal-title":"N Engl J Med"},{"issue":"1","key":"1380_CR104","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/oby.24184","volume":"33","author":"S Wharton","year":"2025","unstructured":"Wharton S, le Roux CW, Kosiborod MN, Platz E, Brueckmann M, Jastreboff AM, et al. Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE\u2122-1 and \u2013\u20092). Obes (Silver Spring). 2025;33(1):67\u201377. https:\/\/doi.org\/10.1002\/oby.24184.","journal-title":"Obes (Silver Spring)"},{"issue":"9","key":"1380_CR105","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/j.cgh.2024.04.017","volume":"22","author":"SS Shankar","year":"2024","unstructured":"Shankar SS, Daniels SJ, Robertson D, Sarv J, S\u00e1nchez J, Carter D, et al. Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis. Clin Gastroenterol Hepatol. 2024;22(9):1847\u2013e5711. https:\/\/doi.org\/10.1016\/j.cgh.2024.04.017.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"1380_CR106","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jhep.2024.07.006","volume":"82","author":"SA Harrison","year":"2025","unstructured":"Harrison SA, Browne SK, Suschak JJ, Tomah S, Gutierrez JA, Yang J, et al. Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. J Hepatol. 2025;82(1):7\u201317. https:\/\/doi.org\/10.1016\/j.jhep.2024.07.006.","journal-title":"J Hepatol"},{"issue":"7","key":"1380_CR107","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","volume":"30","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037\u201348. https:\/\/doi.org\/10.1038\/s41591-024-03018-2.","journal-title":"Nat Med"},{"issue":"17","key":"1380_CR108","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","volume":"385","author":"SM Francque","year":"2021","unstructured":"Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, et al. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. N Engl J Med. 2021;385(17):1547\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2036205.","journal-title":"N Engl J Med"},{"key":"1380_CR109","unstructured":"ClinicalTrials.gov. A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F. 3 (NATiV3) (NATiV3). 2026."},{"issue":"7","key":"1380_CR110","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.cmet.2025.04.014","volume":"37","author":"JP Rose","year":"2025","unstructured":"Rose JP, Morgan DA, Sullivan AI, Fu X, Inigo-Vollmer M, Burgess SC, et al. FGF21 reverses MASH through coordinated actions on the CNS and liver. Cell Metab. 2025;37(7):1515\u2013e296. https:\/\/doi.org\/10.1016\/j.cmet.2025.04.014.","journal-title":"Cell Metab"},{"issue":"Suppl 4","key":"1380_CR111","doi-asserted-by":"publisher","first-page":"A17","DOI":"10.1136\/gutjnl-2025-BASL.22","volume":"74","author":"W Alazawi","year":"2025","unstructured":"Alazawi W, Sanyal AJ, Schattenberg J, Feng S, Gottwald MD, Mansbach H, et al. P5\u2005Pegozafermin treatment demonstrates long-term benefit in subjects with metabolic dysfunction-associated steatohepatitis and fibrosis: results from the Phase 2b ENLIVEN clinical trial. Gut. 2025;74(Suppl 4):A17\u20138. https:\/\/doi.org\/10.1136\/gutjnl-2025-BASL.22.","journal-title":"Gut"},{"issue":"10504","key":"1380_CR112","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S0140-6736(25)01073-6","volume":"406","author":"M Noureddin","year":"2025","unstructured":"Noureddin M, Frias JP, Neff GW, Lucas KJ, Behling C, Bedossa P, et al. Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet. 2025;406(10504):719\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(25)01073-6.","journal-title":"Lancet"},{"issue":"24","key":"1380_CR113","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1056\/NEJMoa2502242","volume":"392","author":"M Noureddin","year":"2025","unstructured":"Noureddin M, Rinella ME, Chalasani NP, Neff GW, Lucas KJ, Rodriguez ME, et al. Efruxifermin in Compensated Liver Cirrhosis Caused by MASH. N Engl J Med. 2025;392(24):2413\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2502242.","journal-title":"N Engl J Med"},{"issue":"8","key":"1380_CR114","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/s2468-1253(25)00067-6","volume":"10","author":"R Loomba","year":"2025","unstructured":"Loomba R, Kowdley KV, Rodriguez J, Kim NJ, Alvarez AM, Morrow L, et al. Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Gastroenterol Hepatol. 2025;10(8):734\u201345. https:\/\/doi.org\/10.1016\/s2468-1253(25)00067-6.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1380_CR115","unstructured":"ClinicalTrials.gov. A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)\/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis. 2026."},{"issue":"5","key":"1380_CR116","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1097\/hjh.0000000000003394","volume":"41","author":"S Xiong","year":"2023","unstructured":"Xiong S, Yin S, Deng W, Zhao Y, Li W, Wang P, et al. Predictive value of liver fibrosis scores in cardiovascular diseases among hypertensive population. J Hypertens. 2023;41(5):741\u201350. https:\/\/doi.org\/10.1097\/hjh.0000000000003394.","journal-title":"J Hypertens"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-026-01380-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11906-026-01380-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-026-01380-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T11:32:25Z","timestamp":1785583945000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11906-026-01380-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":116,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1380"],"URL":"https:\/\/doi.org\/10.1007\/s11906-026-01380-9","relation":{},"ISSN":["1534-3111"],"issn-type":[{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]},"assertion":[{"value":"12 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"L.B.V. consults for Gerson Lehrman Group, Atheneum Partners, Slingshot Insights, ThirdBridge, receives grant support from Madrigal, Akero, B.D. and W.L. Gore & Associates, and participates in medicolegal consulting outside the submitted work. All other authors have no relevant disclosures.","order":2,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"33"}}